Rituxan shows promise in early stage RA
This article was originally published in Scrip
Executive Summary
Genentech/Roche/Biogen Idec's Rituxan (rituximab) has been shown to decrease the progression of joint damage in patients with early rheumatoid arthritis (RA) when used in combination with methotrexate during a Phase III trial, IMAGE. It was the first first-line trial of the drug for rheumatoid arthritis.